Cognitive impairments, depression and quality of life 1 year after COVID-19 hospital discharge
Öz
Purpose: Following the acute stage of COVID-19, many patients have experienced persistent physical and neuropsychiatric symptoms, regardless of the severity of the illness. Key concerns like fatigue, depressive symptoms, and cognitive impairments have a detrimental effect on psychosocial functioning and quality of life. This study aims to explore cognitive impairments and depression one year after discharge from the hospital for COVID-19, along with implications for quality of life.
Materials and Methods: Patients hospitalized with COVID-19 with mild-moderate disease severity were asked to participate in a 12-month follow-up evaluation. A total of 60 individuals who had recovered from COVID-19 were examined for cognitive functions, depressive symptoms, and quality of life. They were then compared to a healthy comparison group, matched for age and education, who had not been infected with COVID-19.
Results: After 1 year following discharge, cognitive impairment was noted in 21.7% of COVID-19 patients, based on The Montreal Cognitive Assessment, while only 3.3% of the non-COVID-19 control group exhibited the same. Quality of life domains were largely comparable across groups. Depressive symptoms were identified as the main factor affecting quality of life domains in COVID-19 patients.
Conclusion: Despite the potential for cognitive impairment to last for up to a year following hospital discharge, it does not seem to have a negative effect on the quality of life in our group of patients with mild-to-moderate disease severity. However, depressive symptoms were found to be the key indicators of quality of life.
Anahtar Kelimeler
Etik Beyan
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethics approval was obtained from the Istanbul University Cerrahpaşa Ethics Committee, with decision number 380358. The study procedure was fully explained, and written consent was obtained from all participants.
Kaynakça
- Huang L, Yao Q, Gu X, Chen H, Wang W, Xu Y et al. 1-year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747-58.
- Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9:129.
- Nakamura ZM, Nash RP, Laughon SL, Rosenstein DL. Neuropsychiatric complications of COVID-19. Curr Psychiatry Rep. 2021;23:1-9.
- Schou TM, Joca S, Wegener G, Bay-Richter C. Psychiatric and neuropsychiatric sequelae of COVID-19: a systematic review. Brain Behav Immun. 2021;97:328-48.
- Ceban F, Ling S, Lui LM, Lee Y, Gill H, Teopiz KM et al. Fatigue and cognitive impairment in post-COVID-19 syndrome: a systematic review and meta-analysis. Brain Behav Immun. 2022;101:93-135.
- Miskowiak KW, Johnsen S, Sattler SM, Nielsen S, Kunalan K, Rungby J et al. Cognitive impairments four months after COVID-19 hospital discharge: pattern, severity and association with illness variables. Eur Neuropsychopharmacol. 2021;46:39-48.
- Mendez R, Balanzá-Martínez V, Luperdi SC, Estrada I, Llamas-Velasco S, Martinez-Villalba S et al. Short-term neuropsychiatric outcomes and quality of life in COVID-19 survivors. J Intern Med. 2021;290:621-31.
- Mattioli F, Stampatori C, Righetti F, Sala E, Tomasi C, De Palma G. Neurological and cognitive sequelae of COVID-19: a four month follow-up. J Neurol. 2021;268:4422-8.
- Almeria M, Cejudo JC, Sotoca J, Deus J, Krupinski J. Cognitive profile following COVID-19 infection: clinical predictors leading to neuropsychological impairment. Brain Behav Immun Health. 2020;9:100163.
- Daroische R, Hemminghyth MS, Eilertsen TH, Breitve MH, Chwiszczuk LJ. Cognitive impairment after COVID-19: a review on objective test data. Front Neurol. 2021;12:699582.
